Page last updated: 2024-09-05

lapatinib and alpha-aminopyridine

lapatinib has been researched along with alpha-aminopyridine in 6 studies

Compound Research Comparison

Studies
(lapatinib)
Trials
(lapatinib)
Recent Studies (post-2010)
(lapatinib)
Studies
(alpha-aminopyridine)
Trials
(alpha-aminopyridine)
Recent Studies (post-2010) (alpha-aminopyridine)
1,9193051,4425,8134603,246

Protein Interaction Comparison

ProteinTaxonomylapatinib (IC50)alpha-aminopyridine (IC50)
Botulinum neurotoxin type A Clostridium botulinum1.8
Nitric oxide synthase, endothelialHomo sapiens (human)2.8
Nitric oxide synthase, brainHomo sapiens (human)6
Nitric oxide synthase, brain Rattus norvegicus (Norway rat)9
Nitric oxide synthase, inducibleHomo sapiens (human)1.9
Phosphatidylinositol 4-kinase alphaHomo sapiens (human)7.1
Phosphatidylinositol 4-kinase type 2-betaHomo sapiens (human)7.1
Phosphatidylinositol 4-kinase type 2-alphaHomo sapiens (human)7.1
Phosphatidylinositol 4-kinase betaHomo sapiens (human)7.1

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (66.67)24.3611
2020's2 (33.33)2.80

Authors

AuthorsStudies
Arteaga, CL; Chanthaphaychith, S; Dahlman, K; Rexer, BN1
Axel, U; Baska, F; Greff, Z; Gyulavári, P; Ibolya, K; Kéri, G; Orfi, L; Peták, I; Szántai, KC; Szokol, B; Vantus, T; Zoltán, O1
Liu, P; Xu, B; Zhang, C1
Autret, A; Bertucci, F; Boher, JM; Camerlo, J; Campone, M; Charafe-Jauffret, E; Extra, JM; Gonçalves, A; Guerin, M; Hervieu, A; Isambert, N; Lokiec, F; Pakradouni, J; Provansal, M; Rezai, K; Sabatier, R; Viens, P1
Ait-Oudhia, S; Franco, YL; Mody, H; Perez, L; Ramakrishnan, V; Vaidya, TR1
Hiramoto, M; Hirota, A; Kazama, H; Miyazaki, M; Miyazawa, K; Ogawa, M; Ota, K; Suzuki, S; Takano, N1

Trials

1 trial(s) available for lapatinib and alpha-aminopyridine

ArticleYear
PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 86

    Topics: Administration, Oral; Adult; Aged; Aminopyridines; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Drug Dosage Calculations; Drug Resistance, Neoplasm; Female; France; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Morpholines; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome

2017

Other Studies

5 other study(ies) available for lapatinib and alpha-aminopyridine

ArticleYear
Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.
    Breast cancer research : BCR, 2014, Jan-23, Volume: 16, Issue:1

    Topics: Aminopyridines; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Mice; Mice, Nude; Morpholines; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays

2014
[Development and biochemical characterization of EGFR/c-Met dual inhibitors].
    Acta pharmaceutica Hungarica, 2013, Volume: 83, Issue:4

    Topics: Afatinib; Aminopyridines; Anilides; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Computer Simulation; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imidazoles; Lapatinib; Lung Neoplasms; Molecular Structure; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Pyrazines; Pyrazoles; Pyridines; Pyridones; Quinazolines; Quinolines

2013
Addition of the p110α inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:11

    Topics: Aminopyridines; Animals; Antibodies; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Humans; Lapatinib; Mice; Morpholines; ortho-Aminobenzoates; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; PTEN Phosphohydrolase; Pyrimidinones; Quinazolines; Receptor, ErbB-2; Thiazoles; Xenograft Model Antitumor Assays

2016
A quantitative systems pharmacological approach identified activation of JNK signaling pathway as a promising treatment strategy for refractory HER2 positive breast cancer.
    Journal of pharmacokinetics and pharmacodynamics, 2021, Volume: 48, Issue:2

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lapatinib; MAP Kinase Signaling System; Network Pharmacology; Protein Interaction Maps; Protein Kinase Inhibitors; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays

2021
Lysosome‑targeted drug combination induces multiple organelle dysfunctions and non‑canonical death in pancreatic cancer cells.
    Oncology reports, 2022, Volume: 47, Issue:2

    Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Drug Synergism; Endoplasmic Reticulum Stress; Fingolimod Hydrochloride; Humans; Hydroxychloroquine; Lapatinib; Lysosomes; Pancreatic Neoplasms; Sphingosine 1 Phosphate Receptor Modulators

2022